Biomarin Pharmaceutical Stock News

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the biggest news of the week is Johnson & Johnson''s (NYSE: JNJ ) announcement regarding the spin-off of its Consumer Health business. Eton Pharmaceuticals, Inc. (NASDAQ: ETON )''s topiramate oral solution received approval from the Food and Drug Administration for certain types of seizures in patients two years of age and older and as a preventative treatment of migraine in patients 12 years of age and older. Azurity Pharma, the sponsor of the new drug application, had purchased topiramate, along with two other neurology candidates from Eton. Eton is eligible to receive a $5 million milestone payment and also royalties on sales. Oncorus, Inc. (NASDAQ: ONCR ) was among the biggest decliners of the week following the company''s presentation of early-stage data for a cancer immunotherapy candidate at the Society for Immunotherapy of Cancer conference.

BioMarin has 6 commercialised assets in the rare disease space, targeting e.g. lysosomal storage diseases.

The mean of analysts' price targets for BioMarin (BMRN) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst

BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q3 2021 Results - Earnings Call Transcript

BioMarin (BMRN) delivered earnings and revenue surprises of 63.64% and -5.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

A small amount of money can go a long way when you own high-quality companies.

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN RAFAEL, Calif., Oct. 4, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans Harold S.

New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN). S

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN).

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN).

BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.

​​​​​​BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene therapy trial on hold.

SAN RAFAEL, Calif., Sept. 6, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phe